Upstate Active Clinical Trials
Study Title:A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON IN EARLY PARKINSON’S DISEASE
What is the purpose of the study? (in Layman's terms, please describe the study)To assess the efficacy of tavapadon in subjects with early PD.
Upstate Institutional Review Board (IRB) Number:1554516
Patient Age Group:Adults
Principal Investigator:Dragos L Mihaila
What is involved if I participate?
- How long is the study?
Approximately 7 months.
Who can I contact for more information?
Name: Marielle N Posmik